文献速递骨质疏松与代谢性骨病

死亡率风险降低因双膦酸盐类别而异:一项15年观察性研究

Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
PubMed 文献 · Osteoporos Int · 2019-01-03

这项前瞻性队列研究纳入加拿大9个中心1995至2013年随访的6120名50岁以上参与者,按倾向评分匹配比较不同双膦酸盐使用者与未治疗者的死亡风险。含氮双膦酸盐与未治疗相比死亡风险显著降低34%(配对HR 0.66,95%CI 0.48-0.91),而非含氮双膦酸盐依替膦酸二钠未见显著关联(配对HR 0.89,95%CI 0.66-1.20)。

要点

  • 含氮双膦酸盐(阿仑膦酸钠、利塞膦酸钠)与未治疗匹配对照相比死亡风险显著降低34%(配对HR 0.66,95%CI 0.48-0.91)。
  • 非含氮双膦酸盐依替膦酸二钠与未治疗相比死亡风险无显著差异(配对HR 0.89,95%CI 0.66-1.20)。

核心结论

  • 与未治疗相比,含氮双膦酸盐而非非含氮双膦酸盐似乎与更好的生存相关。

研究设计与样本

  • 前瞻性队列研究,数据来自基于人群的加拿大骨质疏松多中心研究(Canadian Multicentre Osteoporosis Study),9个加拿大中心,随访1995年至2013年。
  • 共6120名50岁以上参与者,其中使用双膦酸盐者2048名女性与308名男性,未接受骨质疏松药物治疗者1970名女性与1794名男性。
  • 按倾向评分(年龄、性别、共病、脆性骨折状态)及开始用药时间进行1:1匹配,分别构建依替膦酸二钠(n=599)、阿仑膦酸钠(n=498)、利塞膦酸钠(n=213)三个使用者与未治疗匹配队列。
  • 采用配对多变量Cox比例风险模型评估双膦酸盐使用者与匹配未使用者的死亡风险。

主要发现

  • 含氮双膦酸盐(阿仑膦酸钠和利塞膦酸钠)与未治疗相比死亡风险降低(配对HR 0.66,95%CI 0.48-0.91)。
  • 非含氮双膦酸盐依替膦酸二钠与未治疗相比死亡风险无显著差异(配对HR 0.89,95%CI 0.66-1.20)。

关键数值与推荐

  • 含氮双膦酸盐 vs 未治疗:配对HR 0.66(95%CI 0.48-0.91)。
  • 依替膦酸二钠 vs 未治疗:配对HR 0.89(95%CI 0.66-1.20)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性;摘要与结论中未列出具体局限条目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In this prospective cohort of 6120 participants aged 50+, nitrogen-bisphosphonates but not non-nitrogen bisphosphonates were associated with a significant 34% mortality risk reduction compared to non-treated propensity score matched controls. These findings open new avenues for research into mechanistic pathways. INTRODUCTION: Emerging evidence suggests that bisphosphonates (BP), first-line treatment of osteoporosis, are associated with reduced risks for all-cause mortality. This study aimed to determine the association between different BP types and mortality risk in participants with or without a fracture. METHODS: A prospective cohort study of users of different BPs matched to non-users by propensity score (age, gender, co-morbidities, fragility fracture status) and time to starting the BP medication from the population-based Canadian Multicentre Osteoporosis Study from nine Canadian centres followed from 1995 to 2013. Mortality risk for bisphosphonate users vs matched non-users was assessed using pairwise multivariable Cox proportional hazards models. RESULTS: There were 2048 women and 308 men on BP and 1970 women and 1794 men who did not receive medication for osteoporosis. The relationship between BP and mortality risk was explored in three separate 1:1 propensity score-matched cohorts of BP users and no treatment (etidronate, n = 599, alendronate, n = 498, and risedronate n = 213). Nitrogen BP (n-BP) (alendronate and risedronate) was associated with lower mortality risks [pairwise HR, 0.66 (95% CI, 0.48-0.91)] while the less potent non-n-BP, etidronate, was not [pairwise HR: 0.89 (95% CI, 0.66-1.20)]. A direct comparison between n-BP and etidronate (n = 340 pairs) also suggested a better survival for n-BP [paired HR, 0.47 (95%CI, (95% CI, 031-0.70)] for n-BP vs. etidronate]. CONCLUSION: Compared to no treatment, nitrogen but not non-nitrogen bisphosphonates appear to be associated with better survival.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Bliuc D, Tran T, van Geel T, et al. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporos Int. 2019. PMID: 30607457. doi:10.1007/s00198-018-4806-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。